Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 4, 2011, Pages 953-958

  Martinotti, Giovanni ^a,b   Andreoli, Sara ^a   Reina, Daniela ^a   Di Nicola, Marco ^a   Ortolani, Ilaria ^a   Tedeschi, Daniela ^a   Fanella, Fabrizio ^b   Pozzi, Gino ^a   Iannoni, Emerenziana ^a   D'Iddio, Stefania ^a   Prof, Luigi Janiri ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b La Promessa ONLUS   (Italy)

Author keywords

Acetyl l Carnitine; Alcohol; Anhedonia; Melancholia; Negative symptoms

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LEVACECARNINE; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL ABSTINENCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANHEDONIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BECH RAFAELSEN MELANCHOLIA SCALE; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MELANCHOLIA; NAUSEA; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS; SIDE EFFECT; SNAITH HAMILTON PLEASURE SCALE; TREATMENT DURATION; VISUAL ANALOGUE SCALE FOR ANHEDONIA;

ACETYLCARNITINE; ADOLESCENT; ADULT; AGED; ALCOHOLISM; DEPRESSIVE DISORDER; DIAGNOSIS, DUAL (PSYCHIATRY); DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EDUCATIONAL STATUS; EMPLOYMENT; ENDPOINT DETERMINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 79956028427     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.01.013     Document Type: Article

References (60)

1. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl 1989, 7:49-58.
2. Aureli T., Miccheli A., Ricciolini R., Di Cocco M.E., Ramacci M.T., Angelucci L., et al. Aging brain: effect of acetyl-L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy. Brain Res 1990, 526(1):108-112.
3. Bech P. The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure. Acta Psychiatr Scand 2002, 106:252-264.
4. Bella R., Biondi R., Raffaele R., Pennisi G. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 1990, 10(6):355-360.
5. Bovasso G.B. Cannabis abuse as a risk factor for depressive symptoms. Am J Psychiatry 2001, 158:2033-2037.
6. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983, 63:1420-1480.
7. Burlina A.P., Sershen H., Debler E.A., Lajtha A. Uptake of Acetyl-L-Carnitine in the brain. Neurochem Res 1989, 1989(14):489-493.
8. Calvani M., Carta A. Acetyl-L-carnitine: its role in neuronal metabolism. Alzheimer's disease-new treatment strategies 1992, Marcel Dekker, New York. Z.S. Khachaturian, J.P. Blass (Eds.).
9. Cardace G., Marzo A. Binding of L-carnitine, Acetyl-L-carnitine and propionyl-L-carnitine to: a) plasma proteins of dogs and humans; b) albumin. Research Report No. 102-87 1993, September 22.
10. Chiechio S., Copani A., Gereau R.W., Nicoletti F. Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs 2007, (1):31-38. discussion 45-46.
11. De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 2007, 21(1):39-43. discussion 45-6.
12. De Simone C., Catania S., Trinchieri V., Tzantzoglou S., Calvani M., Bagiella E. Ameliorating of the depression of HIV-infected subjects with L-acetyl-carnitine therapy. J Drug Dev 1988, 1(3):163-166.
13. Evans J.D., Jacobs T.F., Evans E.W. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother 2008, 42(11):1686-1691.
14. Falchetto S., Kato G., Provini L. The action of carnitines on cortical neurons. Can J Physiol Pharmacol 1971, 49:1-7.
15. First M.B., Spitzer R.L., Gibbon M., Williams B.W., Benjamin L. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) 1990, Biometrics Research Department, New York State Psychiatric Institute, New York, New York.
16. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
17. Fulgente T., Onorj M., Del Re M.L., Ferracci F., Bazzano S., Ghilardi M.F., et al. Laevo-acetylcarnitine treatment of senile depression. Clin Trials J 1990, 27:155-163.
18. Garzya G., Corallo D., Fiore A., Lecciso G., Petrelli G., Zotti C. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990, 16(2):101-106.
19. Gawin F.H., Ellinwood E.H. Cocaine and other stimulants. Actions, abuse and treatment. N Engl J Med 1988, 318:1173-1182.
20. Gecele M.G., Francesetti G., Meluzzi A. Acetyl-L-carnitine in aged subjets with major depression: clinical efficacy and effects on the circadian rhythm of cortisol. Dementia 1991, 2:3337.
21. Gibson G.E., Shimada M. Studies on the metabolic pathway of the acetyl group for acetylcholine syntesis. Biochem Pharmacol 1980, 29:167-174.
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. DHEW Publication No. (ADM) 1976, 76-338.
23. Heinz A., Schmidt L.G., Reischies F.M. Anhedonia in schizophrenic, depressed, or alcohol dependent patients: neurobiological correlates. Pharmacopsychiatry 1994, 27:7-10.
24. Janiri L., Falcone M., Persico A., Tempesta E. Activity of L-carnitine and L-acetylcarnitine on cholinoceptive neocortical neurons of the rat in vivo. J Neural Transm Gen Sect 1991, 86(2):135-146.
25. Janiri L., Martinotti G., Dario T., Reina D., Paparello F., Pozzi G., et al. Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study. Neuropsychobiology 2005, 52(1):37-44.
26. Janiri L., Martinotti G., Tonioni F., Ghelardini C., Nicolai R., Galeotti N., et al. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome. Clin Neuropharmacol 2009, 32(1):35-40.
27. Janiri L., Tempesta E. A pharmacological profile of the effects of carnitine and acetyl carnitine on the central nervous system. J Clin Pharmacol Res 1983, 3:295-306.
28. Juliet P.A., Balasubramaniam D., Balasubramaniam N., Panneerselvam C. Carnitine: a neuromodulator in aged rats. J Gerontol A Biol Sci Med Sci 2003, 58(11):970-974.
29. Kido Y., Tamai I., Ohnari A., Sai Y., Kagami T., Nezu J., et al. Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 2001, 79(5):959-969.
30. Mancinelli A., Longo A., Shanahan K., Sai Y., Kagami T., Nezu J., et al. Disposition of L-carnitine and acetil-L-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther 1995, 274:1122-1128.
31. Martignoni E., Facchinetti F., Sances G., Petraglia F., Nappi G., Genazzani A.R. Acetyl-L-carnitine acutely administered raises beta-endorphin and cortisol plasma levels in humans. Clin Neuropharmacol 1988, 11(5):472-477.
32. Martinotti G., Cloninger C.R., Janiri L. Temperament and character inventory dimensions and anhedonia in detoxified substance-dependent subjects. Am J Drug Alcohol Abuse 2008, 34(2):177-183.
33. Martinotti G., Di Nicola M., Reina D., Andreoli S., Focà F., Cunniff A., et al. Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse 2008, 43(3-4):271-284.
34. Martinotti G., Reina D., Di Nicola M., Andreoli S., Tedeschi D., Ortolani I., et al. Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: a randomized, double-blind, placebo-controlled pilot trial. Alcohol Alcohol 2010, 245(5):449-455.
35. Martin-Soelch C., Chevalley A.F., Kunig G., Missimer J., Magyar S., Mino A., et al. Changes in reward-induced brain activation in opiate addicts. Eur J Neurosci 2001, 14:1360-1368.
36. Marzo A., Arrigoni Martelli E., Urso R., Rocchetti M., Rizza V., Kelly J.G. Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers (1989). Eur J Clin Pharmacol 1989, 37(1):59-63.
37. Miller N.S., Summers G.L., Gold M.S. Cocaine dependence: alcohol and other drug dependence and withdrawal characteristics. J Addict Disord 1993, 12:25-35.
38. Mottola C.A. Measurement strategies: the visual analogue scale. Decubitus 1993, 6(5):56-58.
39. Nakamura J., Koh N., Sakakibara F., Hamada Y., Hara T., Sasaki H., et al. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozocin-diabetic rats. J Pharmacol Exp Ther 1998, 287:897-902.
40. Nasca D., Zurria G., Aguglia E. Action of acetyl-L-carnitine in association with mianserine on depressed people. New Trends Clin Neuropharmacol 1989, 3(4):225-230.
41. Parnetti L., Gaiti A., Mecocci P., Cadini D., Senin U. Pharmacokinetics of i.v. and oral Acetyl-L-carnitine in a multiple dosage regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol 1992, 42:89-93.
42. Pettegrew J.W., Levine J., Gershon S., Stanley J.A., Servan-Schreiber D., Panchalingam K., et al. 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 2002, 4(1):61-66.
43. Pozzi G., Martinotti G., Reina D., Dario T., Frustaci A., Janiri L., et al. The assessment of post-detoxification anhedonia: influence of clinical and psychosocial variables. Subst Use Misuse 2008, 43(5):722-732.
44. Rossini M., Di Munno O., Valentini G., Bianchi G., Biasi G., Cacace E., et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol 2007, 25(2):182-188.
45. Ruggenenti P., Cattaneo D., Loriga G., Ledda F., Motterlini N., Gherardi G., et al. Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk. Effects of Acetyl-L-Carnitine Therapy. Hypertension 2009, 54(3):567-574.
46. Schatzberg A.F., Nemeroff C.B. Textbook of Psychopharmacology 1998, American Psychiatric Press.
47. Scheggi S., Rauggi R., Nanni G., Tagliamonte A., Gambarana C. Repeated acetyl-l-carnitine administration increases phospho-Thr34 DARPP-32 levels and antagonizes cocaine-induced increase in Cdk5 and phospho-Thr75 DARPP-32 levels in rat striatum. Eur J Neurosci 2004, 19(6):1609-1620.
48. Sigma-Tau Research Division Absolute bioavailability of Acetyl-L-Carnitine Hydrochloride and bio equivalence of the clinical dosage form. Study No. ST GW91001 2003.
49. Sima, A.A., Calvani, M., Mehra, M., Amato, A., Acetyl-L-Carnitine Study Group., Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diab Care 2005, 28(1):89-94.
50. Snaith R.P., Hamilton M., Morley S., Humayan A., Hargreaves D., Trigwell P. A scale for the assessment of hedonic tone. The Snaith Hamilton Pleasure Scale. Br J Psychiatry 1995, 167:99-103.
51. Standhart H. Blocking of GABA activated chloride currents by acetylcholine and acetylcarnitine: a patch-clamp research on colliculus superior cultures of the rat. Data on File Sigma-Tau Industries 1998.
52. Tempesta E., Casella L., Pirrongelli C., Janiri L., Calvani M., Ancona L. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp. Clin Res 1987, 13(7):417-423.
53. Tempesta E., Janiri L., Pirrongelli C. Stereospecific effects of acetylcarnitine on the spontaneous activity of brainstem neurones and their responses to acetylcholine and serotonin. Neuropharmacology 1985, 24(1):43-50.
54. Torrioli M.G., Vernacotola S., Peruzzi L., Tabolacci E., Mila M., Militerni R., et al. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet 2008, 146(7):803-812.
55. Villa R.F., Gorini A. Action of L-acetylcarnitine on different cerebral mitochondrial populations from hippocampus and striatum during aging. Neurochem Res 1991, 16(10):1125-1132.
56. Villardita C., Smirni P., Vecchio I. L-Acetylcarnitine in depressed elderly patients. Eur Rev Med Pharmacol Sci 1984, 62:341-344.
57. Virmani A., Gaetani F., Imam S., Binienda Z., Ali S. The protective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction. Ann NY Acad Sci 2002, 965:225-232.
58. Volkow N.D., Fowler J.S., Wang G.J., Goldstein R.Z. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem 2002, 78:610-624.
59. White H.L., Scates P.W. Acetyl-L-carnitine as a precursor of acetylcholine. Neurochem Res 1990, 15:597-601.
60. Zanardi R., Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 2006, 16(4):281-287.